Viking Therapeutics has initiated the second part of a maintenance study for its obesity drug VK2735, exploring various oral and subcutaneous dosing regimens to maintain weight loss. This development follows positive results from the first part of the study and aims to assess the safety, tolerability, and efficacy of different maintenance options, potentially broadening the drug's market appeal.
Viking Therapeutics announced the start of Part 2 of its maintenance dosing study for VK2735, an obesity drug. This part of the study will investigate various oral and additional subcutaneous dosing regimens to maintain initial weight loss, building on positive results from Part 1. This is significant because an effective oral maintenance option could greatly expand VK2735's market potential and patient adherence compared to injectable-only treatments. For traders, this represents a moderate positive catalyst for VKTX, as successful results could de-risk the drug's development and enhance its competitive profile against established players like Eli Lilly and Novo Nordisk. The long-term implication is a potential blockbuster drug, while short-term focus will be on the safety and efficacy data from this exploratory study.